Ipsen (IPN) Q3 2025 TU earnings summary

Executive summary

• Total sales grew 13.7% in Q3 and 12.1% year-to-date at constant exchange rates, with strong contributions from all therapeutic areas, notably Iqirvo, Bylvay, and Somatuline.

• Upgraded full-year 2025 guidance: sales growth now expected around 10% (previously above 7%) and core operating margin around 35% (previously more than 32%).

• Portfolio outside Somatuline grew 16.7% in Q3 and 12.3% year-to-date; rare disease sales doubled both in Q3 and year-to-date, led by Bylvay and Iqirvo.

• Significant pipeline progress, including the proposed acquisition of ImCheck Therapeutics for EUR 350 million and positive data for IPN10200.

• Regulatory approvals for Bylvay in Japan and Cabometyx in the EU for new indications.

Financial highlights

• Q3 2025 total sales reached €915m, up 13.7% year-over-year; YTD sales at €2,735m, up 12.1%.

• Rare Disease portfolio sales surged 109.1% in Q3 and 101.0% YTD, driven by Bylvay and Iqirvo.

• Oncology sales up 7% in Q3 and 6.6% YTD; Neuroscience sales rose 9.1% in Q3 and 9.5% YTD.

• Somatuline sales increased 11.7% YTD, benefiting from limited generic competition.

• Adverse currency impact of -2.6 percentage points on YTD 2025 sales.

Outlook and guidance

• Full-year 2025 total sales growth expected around 10% at constant exchange rates, with core operating margin guidance raised to around 35% of total sales.

• Currency headwinds expected to reduce total sales by about 3%.

• Anticipates gradual Somatuline erosion in 2026 as generics enter, but expects continued growth from other portfolio areas.

• R&D as a percentage of sales expected to slightly increase from 20% in 2026 due to pipeline investments.

• Guidance assumes limited impact from lanreotide generics and accelerated growth in other products.